BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 21630262)

  • 1. T cells raised against allogeneic HLA-A2/CD20 kill primary follicular lymphoma and acute lymphoblastic leukemia cells.
    Abrahamsen IW; Kjellevoll S; Greve-Isdahl M; Mensali N; Wälchli S; Kumari S; Loland BF; Egeland T; Kolstad A; Olweus J
    Int J Cancer; 2012 Apr; 130(8):1821-32. PubMed ID: 21630262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of CD19 and CD20 peptides for induction of antigen-specific CTLs against B-cell malignancies.
    Bae J; Martinson JA; Klingemann HG
    Clin Cancer Res; 2005 Feb; 11(4):1629-38. PubMed ID: 15746068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies.
    Jahn L; van der Steen DM; Hagedoorn RS; Hombrink P; Kester MG; Schoonakker MP; de Ridder D; van Veelen PA; Falkenburg JH; Heemskerk MH
    Oncotarget; 2016 Nov; 7(47):77021-77037. PubMed ID: 27776339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting B cell leukemia with highly specific allogeneic T cells with a public recognition motif.
    Abrahamsen IW; Stronen E; Wälchli S; Johansen JN; Kjellevoll S; Kumari S; Komada M; Gaudernack G; Tjonnfjord G; Toebes M; Schumacher TN; Lund-Johansen F; Olweus J
    Leukemia; 2010 Nov; 24(11):1901-9. PubMed ID: 20844564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-cell cloning of human, donor-derived antileukemia T-cell lines for in vitro separation of graft-versus-leukemia effect from graft-versus-host reaction.
    Montagna D; Daudt L; Locatelli F; Montini E; Turin I; Lisini D; Giorgiani G; Bernardo ME; Maccario R
    Cancer Res; 2006 Jul; 66(14):7310-6. PubMed ID: 16849581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoreactive, cytotoxic T lymphocytes specific for peptides derived from normal B-cell differentiation antigens in healthy individuals and patients with B-cell malignancies.
    Grube M; Rezvani K; Wiestner A; Fujiwara H; Sconocchia G; Melenhorst JJ; Hensel N; Marti GE; Kwak LW; Wilson W; Barrett JA
    Clin Cancer Res; 2004 Feb; 10(3):1047-56. PubMed ID: 14871984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.
    Braza MS; Klein B; Fiol G; Rossi JF
    Haematologica; 2011 Mar; 96(3):400-7. PubMed ID: 21109686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Umbilical cord blood T cells respond against the Melan-A/MART-1 tumor antigen and exhibit reduced alloreactivity as compared with adult blood-derived T cells.
    Merindol N; Grenier AJ; Caty M; Charrier E; Duval A; Duval M; Champagne MA; Soudeyns H
    J Immunol; 2010 Jul; 185(2):856-66. PubMed ID: 20543110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promiscuity of the AlloHLA-A2 restricted T cell repertoire hampers the generation of minor Histocompatibility antigen-specific cytotoxic T cells across HLA barriers.
    Oosten LE; Blokland E; Kester MG; Falkenburg JH; van Halteren AG; Goulmy E
    Biol Blood Marrow Transplant; 2007 Feb; 13(2):151-63. PubMed ID: 17241921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid monitoring of immune reconstitution after allogeneic stem cell transplantation--a comparison of different assays for the detection of cytomegalovirus-specific T cells.
    Abu-Khader A; Krause S
    Eur J Haematol; 2013 Dec; 91(6):534-45. PubMed ID: 23952609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia.
    Yotnda P; Garcia F; Peuchmaur M; Grandchamp B; Duval M; Lemonnier F; Vilmer E; Langlade-Demoyen P
    J Clin Invest; 1998 Jul; 102(2):455-62. PubMed ID: 9664088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apoptosis Susceptibility Prolongs the Lack of Memory B Cells in Acute Leukemic Patients After Allogeneic Hematopoietic Stem Cell Transplantation.
    Mensen A; Oh Y; Becker SC; Hemmati PG; Jehn C; Westermann J; Szyska M; Göldner H; Dörken B; Scheibenbogen C; Arnold R; Na IK
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1895-906. PubMed ID: 26271190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting B-cell neoplasia with T-cell receptors recognizing a CD20-derived peptide on patient-specific HLA.
    Mensali N; Ying F; Sheng VO; Yang W; Walseng E; Kumari S; Fallang LE; Kolstad A; Uckert W; Malmberg KJ; Wälchli S; Olweus J
    Oncoimmunology; 2016 May; 5(5):e1138199. PubMed ID: 27467957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Collateral damage of nonhematopoietic tissue by hematopoiesis-specific T cells results in graft-versus-host disease during an ongoing profound graft-versus-leukemia reaction.
    van der Zouwen B; Kruisselbrink AB; Frederik Falkenburg JH; Jedema I
    Biol Blood Marrow Transplant; 2014 Jun; 20(6):760-9. PubMed ID: 24607556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mismatched human leukocyte antigen class II-restricted CD8⁺ cytotoxic T cells may mediate selective graft-versus-leukemia effects following allogeneic hematopoietic cell transplantation.
    Hirosawa T; Torikai H; Yanagisawa M; Kamei M; Imahashi N; Demachi-Okamura A; Tanimoto M; Shiraishi K; Ito M; Miyamura K; Shibata K; Kikkawa F; Morishima Y; Takahashi T; Emi N; Kuzushima K; Akatsuka Y
    Cancer Sci; 2011 Jul; 102(7):1281-6. PubMed ID: 21466613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
    Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS
    Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD.
    Bishara A; De Santis D; Witt CC; Brautbar C; Christiansen FT; Or R; Nagler A; Slavin S
    Tissue Antigens; 2004 Mar; 63(3):204-11. PubMed ID: 14989709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans.
    Jensen MC; Popplewell L; Cooper LJ; DiGiusto D; Kalos M; Ostberg JR; Forman SJ
    Biol Blood Marrow Transplant; 2010 Sep; 16(9):1245-56. PubMed ID: 20304086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Responses to donor lymphocyte infusion for acute lymphoblastic leukemia may be determined by both qualitative and quantitative limitations of antileukemic T-cell responses as observed in an animal model for human leukemia.
    Nijmeijer BA; van Schie ML; Verzaal P; Willemze R; Falkenburg JH
    Exp Hematol; 2005 Oct; 33(10):1172-81. PubMed ID: 16219539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes.
    Wang J; Press OW; Lindgren CG; Greenberg P; Riddell S; Qian X; Laugen C; Raubitschek A; Forman SJ; Jensen MC
    Mol Ther; 2004 Apr; 9(4):577-86. PubMed ID: 15093188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.